Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – Equities researchers at HC Wainwright increased their FY2024 earnings per share estimates for Basilea Pharmaceutica in a research report issued on Thursday, April 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $2.27 per share for the year, up from their prior estimate of $1.78. The consensus estimate for Basilea Pharmaceutica’s current full-year earnings is $2.06 per share.
Basilea Pharmaceutica Stock Performance
OTCMKTS BPMUF opened at $40.75 on Monday. Basilea Pharmaceutica has a 52 week low of $38.60 and a 52 week high of $40.75. The business has a 50 day moving average price of $40.36 and a 200-day moving average price of $41.83.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Stories
- Five stocks we like better than Basilea Pharmaceutica
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 4 Golden Crosses With Double-Digit Upside Ahead
- How to Invest in Blue Chip Stocks
- All-Aboard! Greenbrier Companies Breaks Out, New Highs Ahead
- How to Start Investing in Real Estate
- 3 High Dividend Socks to Replace Lower Savings Yields Ahead
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
